Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.62 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | MMP12 | P39900 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | AGXT | P21549 | 2/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27577784 | 0.87 | HCAR2 (0.64) | ALDH1A1HCAR2MMP1MMP2MMP9 | |
| SCHEMBL7659252 | 0.84 | HCAR2 (0.60) | ALDH1A1HCAR2MMP1MMP2MMP9 | |
| SCHEMBL2659547 | 0.84 | ALDH1A1 (0.61) | ALDH1A1HCAR2MMP1MMP2MMP9 | |
| SCHEMBL19831539 | 0.81 | HCAR2 (0.57) | ALDH1A1HCAR2MMP1MMP2MMP9 | |
| SCHEMBL13467287 | 0.81 | HCAR2 (0.57) | ALDH1A1HCAR2MMP1MMP2MMP9 | |
| SCHEMBL7975207 | 0.81 | ALDH1A1 (0.60) | ALDH1A1HCAR2MMP1MMP2MMP9 | |
| SCHEMBL134797 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HCAR2MMP1MMP2MMP9 | |
| SCHEMBL11237868 | 0.80 | ALDH1A1 (0.61) | ALDH1A1MMP2MMP9MMP12IDO1 | |
| SCHEMBL11226742 | 0.80 | ALDH1A1 (0.61) | ALDH1A1HCAR2MMP1MMP2MMP9 | |
| SCHEMBL28046532 | 0.80 | ALDH1A1 (0.61) | ALDH1A1HCAR2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922329-B | Process and intermediates for the preparation of water-soluble taxane derivatives | 江苏恩华络康药物研发有限公司 | 2020-11-24 | — | — | CN | claimed |
| CN-107922329-A | It is used to prepare the method and intermediate of water-soluble taxane analog derivative | 江苏恩华络康药物研发有限公司 | 2018-04-17 | — | — | CN | claimed |
| CN-107056767-B | Process and intermediates for the preparation of water-soluble taxane derivatives | 江苏恩华络康药物研发有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-108779096-B | Fluorine-substituted cyclopropylamine compounds, and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-07-01 | — | — | CN | disclosed |
| CN-107922329-B | Process and intermediates for the preparation of water-soluble taxane derivatives | 江苏恩华络康药物研发有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-17 | — | — | US | disclosed |
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-04 | — | — | US | disclosed |
| EP-3431471-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USERS THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-01-23 | — | — | EP | disclosed |
| CN-108779096-A | A kind of fluorine-substituted cyclopropylamine class compound and preparation method thereof, pharmaceutical composition and purposes | 中国科学院上海药物研究所 | 2018-11-09 | — | — | CN | disclosed |
| CN-107922329-A | It is used to prepare the method and intermediate of water-soluble taxane analog derivative | 江苏恩华络康药物研发有限公司 | 2018-04-17 | — | — | CN | disclosed |
| EP-2257524-B1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | BRICKELL BIOTECH INC (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-1988078-A1 | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders | Ortho-McNeil Pharmaceutical, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1177168-B1 | CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-0923555-B1 | CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1184374-A1 | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6069254-A | Carboxamide derivatives of piperidine for the treatment of thrombosis disorders | ORTHO PHARMACEUTICAL CORP. (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0923555-A1 | CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1997041102-A1 | CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-11-06 | — | — | WO | disclosed |
| US-4415571-A | HYPOTENSIVE AGENTS; THROMBOSIS; ANTICOAGULANTS; CARDIOVASCULAR DISORDDERS | BASF AKTIENGESELLSCHAFT (DE) | 1983-11-15 | — | — | US | disclosed |
| US-4000297-A | GASTROENTERIC ACTIVITY | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100507-A1 | FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | SETDB1, KDM1B, SETD7 | ALDH1A1 354/4885HCAR2 891/4885MMP1 3456/4885 |
| US-10836743-B2 | Fluorinated cyclopropylamine compound, preparation method therefor, pharmaceutical composition thereof, and uses thereof | SETDB1, KDM1B, SETD7 | ALDH1A1 354/4885HCAR2 891/4885MMP1 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.